RxDoctor Payments Data

Colbert Perez, MD

Interventional Cardiology · Lubbock, TXNPI 1831484773

Payments from drug & device makers

$40,635in general payments, 2019–2025

Across 892 payments — averaging $45.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$27K
  • Medtronic$4K
  • Abbott$2K
  • Cardiovascular Systems Inc.$1K
  • AstraZeneca$743
  • Johnson & Johnson$644
  • plus $6K from 43 others

What the payments were for

  • Speaking & faculty fees$24,03759%
  • Travel & lodging$1,3033%
  • Food & beverage$15,03437%
  • Education$2611%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$40,635 in reported general payments places this provider in the 75th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$1,714,449
Medicare patients
1,750
Services billed
15,475

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban960$785,349
XareltoRivaroxaban520$382,747
EntrestoSacubitril/Valsartan251$254,612
FarxigaDapagliflozin Propanediol339$234,100
Repatha SureclickEvolocumab283$210,834
JardianceEmpagliflozin161$126,442
BrilintaTicagrelor111$70,867
OzempicSemaglutide42$42,533
MounjaroTirzepatide31$32,262
Praluent PenAlirocumab37$21,742
MultaqDronedarone Hcl17$21,348
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$17,391
VascepaIcosapent Ethyl38$16,428
InpefaSotagliflozin14$15,847
Valsartan670$13,117

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$251$785,349960 claims
Johnson & JohnsonXarelto$644$382,747520 claims
AstraZenecaFarxiga, Brilinta$743$304,967450 claims
NovartisEntresto$423$254,612251 claims
Boehringer IngelheimJardiance$445$126,442161 claims
Novo NordiskOzempic$129$42,53342 claims
Lilly USA, LLCMounjaro$14$32,26231 claims
Sanofi-aventis U.S. LLCMultaq$73$21,34817 claims
Lexicon Pharmaceuticals, Inc.Inpefa$47$15,84714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Lubbock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →